Stock listing

NASDAQ:IKT Inhibikase Therapeutics, Inc. Stock

Home listing (NASDAQ) of Inhibikase Therapeutics, Inc.

Follow Inhibikase Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:IKT

$1.50 USD +0.06 (+4.2%)

Close on Nov 6, 2026

Past year +0.7% · daily closes, Nov 6, 2025 – Nov 6, 2026, adjusted for splits
Day range
$1.44 – $1.53 USDNov 6, 2026
Volume
356,019 sharesNov 6, 2026
Market cap
$209.3M USDAt the close on Nov 6, 2026 · price × 139.5M shares outstanding
52-week range
$1.39 – $2.61 USDLowest and highest trades, Nov 7, 2025 – Nov 6, 2026
Traded on an average day
$1.13M USDMedian day 445,600 shares · last 3 months, Aug 6, 2026 – Nov 6, 2026
Inhibikase Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IKT · Home$1.50 USD+0.06 (+4.2%)356,019$1.44$1.53$1.44$1.44Close on Nov 6, 2026

Daily closes

Last 3 months, Aug 6, 2026 – Nov 6, 2026 · NASDAQ:IKT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.50+0.06+4.2%$1.44$1.53$1.44356,019
$1.44-0.125-8.0%$1.56$1.56$1.43742,652
$1.565+0.085+5.7%$1.56$1.60$1.51675,400
$1.48-0.06-3.9%$1.57$1.59$1.47601,074
$1.54-0.01-0.6%$1.56$1.59$1.47449,231
$1.55-0.12-7.2%$1.67$1.67$1.525437,986
$1.67+0.05+3.1%$1.64$1.695$1.625852,337
$1.62+0.05+3.2%$1.55$1.63$1.53386,644
$1.57+0.05+3.3%$1.55$1.60$1.4951,186,220
$1.52-0.07-4.4%$1.60$1.60$1.50860,469
$1.59-0.04-2.5%$1.60$1.65$1.541408,529
$1.63-0.03-1.8%$1.65$1.65$1.58310,490
$1.66-0.05-2.9%$1.71$1.76$1.64529,005
$1.71+0.065+4.0%$1.65$1.75$1.63363,421
$1.645-0.005-0.3%$1.67$1.72$1.571,331,840
$1.65-0.18-9.8%$1.82$1.82$1.65917,200
$1.83+0.03+1.7%$1.80$1.87$1.795400,700
$1.80+0.04+2.3%$1.73$1.865$1.721,578,900
$1.76-0.085-4.6%$1.85$1.875$1.731,164,500
$1.845-0.125-6.3%$1.95$1.95$1.77741,400
$1.97+0.06+3.1%$1.90$1.98$1.87435,000
$1.91-0.03-1.5%$1.94$1.94$1.86417,300
$1.94-0.04-2.0%$1.95$2.00$1.925444,000
$1.98-0.02-1.0%$1.97$2.04$1.95583,800
$2.000.000.0%$2.00$2.025$1.955407,300
$2.00+0.07+3.6%$1.96$2.016$1.932434,500
$1.93-0.125-6.1%$2.095$2.095$1.93474,700
$2.055+0.035+1.7%$2.03$2.08$1.99579,500
$2.02-0.03-1.5%$2.03$2.05$2.005400,300
$2.05-0.01-0.5%$2.05$2.065$1.94765,100
$2.06-0.04-1.9%$2.10$2.15$2.045447,200
$2.10-0.05-2.3%$2.15$2.17$2.08499,100
$2.15-0.16-6.9%$2.30$2.31$2.14412,300
$2.31+0.11+5.0%$2.23$2.335$2.21468,700
$2.20-0.10-4.3%$2.31$2.32$2.195366,000
$2.300.000.0%$2.31$2.345$2.283,209,700
$2.30-0.01-0.4%$2.31$2.365$2.285475,500
$2.310.000.0%$2.32$2.345$2.26370,500
$2.31-0.08-3.3%$2.40$2.40$2.253480,900
$2.39+0.05+2.1%$2.34$2.425$2.34482,900
$2.34+0.01+0.4%$2.37$2.39$2.323303,200
$2.33-0.08-3.3%$2.37$2.385$2.32332,400
$2.41-0.02-0.8%$2.43$2.45$2.38323,400
$2.43-0.07-2.8%$2.45$2.525$2.43310,500
$2.50-0.02-0.8%$2.49$2.55$2.475247,000
$2.52+0.02+0.8%$2.50$2.61$2.46564,200
$2.50+0.12+5.0%$2.39$2.535$2.39379,000
$2.38+0.07+3.0%$2.30$2.405$2.27523,200
$2.31-0.10-4.1%$2.41$2.44$2.30329,900
$2.41-0.06-2.4%$2.48$2.48$2.371308,000
$2.47-0.02-0.8%$2.48$2.50$2.40202,000
$2.49-0.01-0.4%$2.50$2.51$2.43244,100
$2.500.000.0%$2.53$2.54$2.46453,435
$2.50+0.11+4.6%$2.41$2.54$2.345735,926
$2.39+0.04+1.7%$2.38$2.415$2.37309,300
$2.35-0.10-4.1%$2.45$2.47$2.33540,000
$2.45+0.05+2.1%$2.44$2.515$2.43645,000
$2.40+0.01+0.4%$2.36$2.41$2.31344,000
$2.39-0.02-0.8%$2.41$2.42$2.32489,500
$2.410.000.0%$2.39$2.435$2.37227,900
$2.41+0.01+0.4%$2.43$2.46$2.33360,700
$2.40-0.05-2.0%$2.38$2.47$2.38296,900
$2.45-0.01-0.4%$2.48$2.515$2.41580,700
$2.46-0.01-0.4%$2.44$2.525$2.42479,000
$2.47+0.06+2.5%$2.38$2.475$2.38386,700
$2.41+0.01+0.4%$2.39$2.49$2.385422,900

Splits

1 split · NASDAQ:IKT · every price before a split is adjusted for it

DayRatioWhat
1-for-6Consolidation
Ticker
NASDAQ:IKT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Inhibikase Therapeutics (NASDAQ:IKT) Q2 2024 Earnings Call

    Thu, Aug 15, 2024 · 8:00 AM ET

    Watch Transcript

  • Inhibikase Therapeutics (NASDAQ:IKT) Q1 2024 Earnings Call

    Thu, May 16, 2024 · 8:00 AM ET

    Watch Transcript

  • Inhibikase Therapeutics (NASDAQ:IKT) Q4 2023 Earnings Call

    Thu, Mar 28, 2024 · 8:00 AM ET

    Watch Transcript

Latest news

Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026

Oct 27, 2026

Closed $1.57 (+3.3%) on Oct 27, 2026

Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors

Oct 20, 2026

Closed $1.66 (-2.9%) on Oct 21, 2026

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 2, 2026

Closed $2.00 (0.0%) on Oct 5, 2026

Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity

Aug 11, 2026

Closed $2.40 (-2.0%) on Aug 12, 2026

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

Jul 23, 2026

Closed $2.33 (+7.4%) on Jul 23, 2026

Inhibikase Therapeutics Announces Sale of $50 Million of Shares through its At-the-Market Facility

Jul 15, 2026

Closed $2.06 (0.0%) on Jul 15, 2026

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

Jul 14, 2026

Closed $2.06 (+5.1%) on Jul 14, 2026

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

May 12, 2026

Closed $1.90 (-1.0%) on May 13, 2026

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Apr 7, 2026

Closed $1.76 (-1.7%) on Apr 7, 2026

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)

Apr 6, 2026

Closed $1.79 (-0.6%) on Apr 6, 2026

All Inhibikase Therapeutics, Inc. news

Financings

  • At-the-market programme of common stock

    Aug 11, 2026

    Closed: US$50M in the latest tranche

    Buyers: RA Capital Management (25,000,000 shares of common stock for gross proceeds of $50 million)

    Use of proceeds: With existing cash, to support operations through topline data readout in Part B of the Phase 3 IMPROVE-PAH study

    Closed Jul 14, 2026 · Closed Jul 15, 2026 · Closed Aug 11, 2026

  • Public offering of common stock and pre-funded warrants

    Nov 21, 2025

    Announced: about US$100M · US$1.45 a share · Jefferies +6

    Dealers: Jefferies (lead), BofA Securities (lead), Cantor (lead), LifeSci Capital (co-lead), Oppenheimer & Co. (co-lead), H.C. Wainwright & Co., Ladenburg Thalmann & Co. Inc.

    Announced Nov 21, 2025

  • At-the-market programme of common stock

    Dec 5, 2024

    Cancelled: up to US$5.66M · H.C. Wainwright & Co., LLC

    Dealers: H.C. Wainwright & Co., LLC (lead)

    Cancelled Dec 5, 2024

Read by 6ix AI from the company's releases

Decks

Inhibikase Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
16 in the last 12 months · 28 in all · newest Oct 27, 2026 · oldest 2024
Calls
11 calls with a replay · 11 with a transcript · latest Aug 15, 2024
Decks
14 decks · latest September 2026

Where Inhibikase Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IKT · Home listing · This pageNASDAQUnited StatesUSD
gettex:IQT0gettexGermanyEUR
BOATS:IKTBOATSUnited StatesUSD
Munich:IQT0MunichGermanyEUR
Stuttgart:IQT0StuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Inhibikase Therapeutics, Inc.